Neyrokhirurgia-Grinberg-2010-pdf
.pdf9. |
9 |
(Vancocin®)
,
( ,
) -
. , -
, , -
.
(-) . .
L : 1 8 .
20-40 µ ( -
>50; , -
-
>200 µ ) 5-10 (
, >10).
: 125 4 -
7-10 ( -
, ).
: 0-7 50 12; 7 : 45 , 12 .
(Cleocin®)
(+) (
, ,
), , Bacteroides fragilis, Toxoplasma gondii. -
( )
,
).
L : 150-450 6 . : 150-900 8 .
: 75, 160 300 .
(Chloromycetin®)
(+) (-) .
( ).
.
L : : 250-750 6 ( -
). : 50 , -
6 . : 0-7 25 1 .
50 , 12 .
) 100 , 6 .
9. |
10 |
( ). -
. -
(-) , .
. -
- , , ,
(>8 ).
, ,
, 2-3 . -
,
( -
;
).
. 3 -
.
.
(Garamycin®)
L : 2
, 1-1,6 8 . -
( max >4 µ , min - <2). : 4 12 .
(Nebcin®)
, ).
L : 2
, 1-1,6 8 .
>60 , 12 . -
( max 7,5-10 µ , min - <2). : 6-7,5 , 6-8 .
(-) ,
.
9. |
11 |
L : 15 , -
8 . >60 , -
12 . ( -
max 15-30 µ ).
(Bactrim®, Septra®)
NB:
). -
( ., -
).
L : 1 (160
+800 ) 12 . 40 + 200
5 (1 ); 20
12 . Max : 320 + 1600 .
L : 8-10
12 .
L ( <2 ): 5 80
+400 ; 125 5% (
, -
75 , 2 ).
. : 8-10 (max 60 ), 6, 8 12 14 .
, Pneumocystis carinii (
): 15-20 ,
6 8 14 .
-
. -
( - -
).
(Primaxin®)
.
, . -
. -
, , Pseudomonas -
. -
9. |
12 |
,
.
: : -
, ,
( ).
-
. , C. difficile.
. L : 0,5-1 30 6 (
500 -
6 , ). : 0-750 , 12 . <3 100
, 6 . >3 60
, 6 .
(Azactam®)
. -
, . (-)
, -
. (
+ ).
H. flu, Bramhamelle,
, (-) . -
, . -
( ., ),
, . <14 .
(Cipro®)
,
-
( ., ).
, -
( ., Maalox®), (Carafate®) -
. ,
6 2 . -
9. |
13 |
. -
.
L 500 12 ( : 750
12 ). : 400 12 ( 60 ).
,
( , -
)3. : 250, 500 750 .
(Floxin®)
. L 400 12 .
9.1.3.
Hemophilus influenza
1.( , -
)
2.Unasyn® ( . .202): , (+) (
H. flu, . )
3.: . .206
4.: . .204
Pseudomonas aeruginosa ( )
(Fortaz®) ( . .204).
,
. -
.
, ,
+ ,
( ,
, ). -
( -
): , -
, , . -(Timentin®) -
. ( )
( -, ,
. ).
9. |
15 |
Clostridium difficile; -
, . -
,
( . .205).
:
-
. 9-5.
Jay P. Sanford, MD “Guide to Antimicrobial Therapy 1991» 1991, pp.101, Antimicrobial Therapy Inc., West Bethesda, MD)
|
- |
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
G |
|
|
|
>800 |
|
|
* |
|
) |
|
|
|
|
|
|
INH |
|
|
|
) |
|
|
|
|
|
|
|
G |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*
, . 9-6 . 9-7, -
, -
4. ,
.
.
>1:8.
9. |
16 |
. 9-6. (
P.T.Frame and R.L.McLaurin in “Pediatric Neurosurgery” by American Association of Neurological Surgeons, pp.594, 1982, published by Grune and Stratton, Orlando, FL)
|
|
|
* |
10 12 |
10 12 |
|
5 6 |
5 6 |
. 9-7.
, . 9-6)
|
|
|
|
|
|||||||
|
|
|
|
|
|
(0-7 ) |
|
|
|
|
|
G |
5 |
|
50 |
|
50 |
|
|
|
|
|
|
|
6 |
6 |
8 |
|
|
|
|
||||
|
3 |
6 |
50 |
|
50 |
50 |
|
|
|||
|
|
|
|
6 |
12 |
|
|
24 |
|
|
|
|
5 |
4 |
100 |
|
100 - |
50 |
|
|
|||
|
|
|
|
6 |
12 |
|
24 |
|
|
||
|
2 |
4 |
50 |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
|
|
|
|
|
|
|
|
3 |
4 |
75 |
|
50 |
|
|
|
|||
|
|
|
|
6 |
8 |
|
|
|
|
|
|
|
2 |
4 |
50 |
|
25 |
|
|
|
|||
|
|
|
|
6 |
8 |
|
|
|
|
|
|
|
2 |
6 |
50 |
|
50 |
|
|
|
|||
|
|
|
|
8 |
12 |
|
|
|
|
|
|
|
2 |
4 |
25 |
|
- |
50 |
|
|
|||
|
|
|
|
6 |
|
|
|
24 |
|
|
|
|
1 |
6 |
25 |
|
25 |
1 |
|
|
|
||
|
|
|
|
6 |
|
|
|
|
|
|
|
|
1,7 |
|
2,5 |
|
2,5 |
|
- |
8 24 |
|||
|
8 |
8 |
12 |
|
* |
|
|
||||
|
1,7 |
|
2,5 |
|
2,5 |
|
- |
8 24 |
|||
|
8 |
8 |
12 |
|
|
|
|
||||
|
7,5 |
|
7,5 |
|
7,5 |
|
- |
12 |
|
|
|
|
12 |
8 |
12 |
|
24 |
|
|
||||
|
7,5 |
|
7,5 |
|
7,5 |
|
- |
12 |
|
|
|
|
12 |
8 |
12 |
|
24 |
|
|
||||
|
1 |
|
|
15 |
|
15 |
5-10 |
||||
|
12 |
|
8 |
12 |
|
|
48-72 |
|
|||
|
2 |
6 |
30 |
|
20 |
1-2 |
- |
||||
|
|
|
|
8 |
12 |
|
|
|
24 † |
||
|
2 |
4 |
50 |
|
20 |
50 |
|
|
|||
|
|
|
|
6 |
12 |
|
|
24 |
|
|
|
|
|
|
9. |
|
17 |
||
|
|
|
|
|
|
|
|
|
2 |
4 |
50 |
|
|
20 |
50 |
|
|
|
6 |
|
12 |
24 |
|
|
2 |
6 |
50 |
|
|
30 |
|
|
|
|
8 ‡ |
|
12 |
|
|
|
2 |
|
75 - |
|
|
|
|
|
12 |
, |
50 |
|
|
|
|
|
|
|
|
- |
|
|
|
|
|
|
12 |
|
|
|
|
Timentin® |
3,1 |
|
|
|
|
||
|
4 |
|
|
|
|
|
|
* « » , -
-
† max 50
‡ max 6
9.2.
5
1.( -
; -
1 )
3.. ,
( -
)
( ., ,
-
) ,
5.1
( , -
)
6.( ,
) -
, -
7.,
:
A.: , -
, ( -
9. |
18 |
, -
),
B. : , ,
1.:
A., -
-
(
)
,
( ., « »). -
( , , -
)
C.(Ancef®, Kefzol®)
, ,
6, -
: 1-2 ( : 25 1) 60 , 6 24
D.S. aureus -
; -
. -
2 , 1 2-3 -
)7
,
2.: , -
( -
, -
). ( ): 15 ( 1 )
, 10 8 24
3.: : , -
, , -